drugset / Trial / NCT03289026

Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

NCT03289026

Phase 4 Completed 770 enrolled Peking University
NaSingle-groupOpen-labelTreatment

Summary

This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics of the population for taking aripiprazole and provide reference for clinical rational drug use.

Timeline

Start
2017-09-01
Primary completion
2020-01-23
Completion
2021-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg Oral
Subject Aripiprazole Other / unclassified 30 mg Oral

Indications